Hervé Affagard, MaaT Pharma CEO
FDA lifts nearly two-year hold on MaaT Pharma's microbiome therapy, opens door to PhIII
After nearly two years, the FDA has decided a microbiome therapy can now be tested in US patients with acute graft-versus-host disease (aGVHD), lifting a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
